WHO approves GSK's Cervarix, but no price agreed
This article was originally published in Scrip
Executive Summary
The World Health Organization has prequalified GlaxoSmithKline's cervical cancer vaccine, Cervarix, meaning the product can be procured by UN agencies and similar organisations for use in developing countries. However, no agreement has been reached on the price of this expensive vaccine to poor countries.